- Revival Pharmaceuticals (RVPH) is a late-stage biopharma company focused on developing **Biloroxazine** for schizophrenia, currently in Phase 3 development, with potential for other neuropsychiatric conditions.  **[1742927_2162557_1]** 
- Clinical trials involving **over 900 patients** have demonstrated **Biloroxazine**'s robust efficacy, particularly for **negative symptoms**, and **durable efficacy** with a low relapse rate.  **[1742927_2162557_1]** **[1742927_2162557_4]** **[1742927_2162557_8]**  The Phase 3 RECOVER one study showed a **10 separation from placebo** in PANSS total score.  **[1742927_2162557_2]** **[1742927_2162557_3]** 
- The drug exhibits a favorable safety profile, with hardly any motor side effects (less than **1%** in Phase 3) and a low discontinuation rate of **35%** in the open-label study, compared to 50-80% for other antipsychotics.  **[1742927_2162557_1]** **[1742927_2162557_5]** **[1742927_2162557_6]** 
- Revival Pharmaceuticals anticipates a Type C meeting with the FDA in **December 2025** (Q4 2025) to discuss pre-NDA feedback, with a potential for early NDA filing in **Q2 2026** and drug approval in early **2027**.  **[1742927_2162557_1]** **[1742927_2162557_6]** **[1742927_2162557_7]** **[1742927_2162557_8]**

Revival Pharmaceuticals Discusses Biloroxazine Clinical Progress and Regulatory Strategy

- Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the pricing of a public offering on **September 18, 2025**, for aggregate gross proceeds of approximately **$9 million**.  **[1742927_0001437749-25-029531_ex_862998.htm:0]** 
- The offering includes **27,000,000 shares** of common stock (or equivalents) along with Series E and Series F warrants to purchase up to **27,000,000 shares** each, at a combined offering price of **$0.335** per share and accompanying warrants.  **[1742927_0001437749-25-029531_ex_862998.htm:0]** **[1742927_0001437749-25-029531_rvph20250919_8k.htm:1]** 
- Both Series E and Series F warrants have an exercise price of **$0.335** per share; Series E warrants expire in **five years**, and Series F warrants expire in **12 months** from the issuance date.  **[1742927_0001437749-25-029531_ex_862998.htm:0]** **[1742927_0001437749-25-029531_rvph20250919_8k.htm:1]** 
- The closing of the offering is expected around **September 22, 2025**, with net proceeds of approximately **$8.1 million** intended for research and development activities, working capital, and general corporate purposes.  **[1742927_0001437749-25-029531_ex_862998.htm:0]** **[1742927_0001437749-25-029531_rvph20250919_8k.htm:1]**

REVIVA PHARMACEUTICALS HOLDINGS (RVPH)